NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs031180120

Registered date:15/02/2019

Efficacy of empagliflozin to type 2 diabetic patients with ICD

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedType2 Diabetes
Date of first enrollment19/04/2019
Target sample size210
Countries of recruitment
Study typeInterventional
Intervention(s)Empagliflozin group: Patients will be treated by empagliflozin 10mg once daily for 24 weeks. Placebo group: Patients will be treated by placebo once daily for 24 weeks.

Outcome(s)

Primary Outcomefrequency of lethal ventricular arrhythmia in implantable cardioverter-defibrillator
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteriaOver 20 years Patients with ICD Type2 Diabetes
Exclude criteriaLiver disease with ALT, AST or ALP x3 ULN Planned CV surgery, angioplasty, stroke and heart failure hospitalization in 6 month eGFR <30 mL/min/1.73 m2 by MDRD equation Nutritional disorders Cancer Nursing, pregnant, or child-bearing age women not using acceptable method of birth control or refusing pregnancy testing Alcohol abuse

Related Information

Contact

Public contact
Name Shinya Fujiki
Address 1-757 Asahimachidori, Chuo-ku, Niigata Niigata Japan 951-8510
Telephone +81-25-227-2185
E-mail shinya_fukuji@yahoo.co.jp
Affiliation Niigata University Graduate School of Medical and Dental Sciences
Scientific contact
Name Tohru Minamino
Address 1-757 Asahimachidori, Chuo-ku, Niigata Niigata Japan 951-8510
Telephone +81-25-227-2185
E-mail t.minamino@juntendo.ac.jp
Affiliation Niigata University Graduate School of Medical and Dental Sciences